# Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP

> **NCT05308472** · PHASE2 · COMPLETED · sponsor: **Disc Medicine, Inc** · enrollment: 75 (actual)

## Conditions studied

- Erythropoietic Protoporphyria

## Interventions

- **DRUG:** DISC-1459
- **DRUG:** DISC-1459
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05308472
- **Lead sponsor:** Disc Medicine, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-31
- **Primary completion:** 2024-02-20
- **Final completion:** 2024-08-23
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05308472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05308472, "Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05308472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*